Clinical Trial Update: Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib hydrochloride with or without bicalutamide in hormone-refractory prostate cancer has completed; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Bicalutamide (Casodex) (bicalutamide)
• Pazopanib (Pazopanib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-05-24